The conventional assessment of response to slow acting antirheumatic drugs depends on multiple clinical and laboratory measures.
clinical practice and therapeutic trials a single unified classification ofresponse is preferable, based on the most sensitive and simple current measures. Whether or not this was practical was determined in a prospective study of two cohorts of patients: 145 given penicillamine 250-500 mg daily in a single dose; 98 sulphasalazine at an initial dose of 500 mg rising after one month to 2 g daily. Both groups were followed up for 12 months. A panel of 11 clinical and laboratory measures were evaluated every three to six months. Most changes had occurred by six months, and this was the optimum time to classify response. Four measures were used to devise a five point (0-4) classification ofresponse from no change to remission. The objective was to evaluate if this approach is appropriate; the best level of each measure to use was not determined. The response index was based on: erythrocyte sedimentation rate <30 mm/h; articular index <3; morning stiffness <15 min; >50% reduction in joint pain. Similar results were obtained with both drugs. The other clinical and laboratory measures gave limited information. This response index is simple and appropriate. It is suitable for use in clinical practice and drug studies, though the optimal values for dividing each clinical and laboratory variable need to be determined. The consensus meeting suggested looking at three clinical measures and one laboratory measure: the articular index, duration of morning stiffness, joint pain, and the ESR (or its equivalent); arbitrary levels for defining response for each of these measures were also proposed. We have examined whether this approach is practical by analysing results in two cohorts of patients with RA treated with penicillamine and sulphasalazine. Our objective was to determine if this was an appropriate method using the levels of response (such as morning stiffness of 15 minutes or less and an ESR of 30 mm/h or less) suggested at the consensus meeting; the optimal levels for each of the clinical and laboratory variables will need to be determined in subsequent studies.
Patients and methods

PATIENTS
We studied two different cohorts of patients with RA: (a) 145 on any specific characteristics of their RA. They were followed up and assessed in detail at 0,3, 6, 9, and 12 months oftreatment. Table 1 Slow acting antirheumatic drgs (18) 12 (17) 36 (18) 3 27 (21) 8 (11) 35 (17) 2 31 (24) 8 (11) 39 (20) 34 (26) 26 (37) 60 (30) 0 15 (11) 16 (23) 31 (15) There was a fairly even distribution of patients between each of the five categories (on the 0-4 scale) with only a slight surfeit of cases in category 1. This distribution was similar with both drugs. The index was very simple to use. It took less than a minute to classify each patient. No complex decisions were needed and it could be done manually without recourse to a calculator or microcomputer.
Discussion
Our results show that it is possible to produce a simple classification of response to treatment that can be applied to more than one SAARD. The measures we used were selected after debate among interested rheumatologists.
Unlike other indices of disease activity,24 our proposed index is simple. It can be calculated retrospectively from data in earlier studies of SAARDs. It can also be related to Pinal's criteria of remission in RA.6 To define a response index in RA will take time and this study shows the approach is practical; possibly, slight variations may be needed in the actual levels of clinical and laboratory indices chosen to indicate response. There is also a need to define the sensitivity and specificity of the criteria in subsequent investigations.
For response criteria to become widely accepted they must be evaluated in various circumstances by a number of experienced clinicians. 
